Maxim raised the firm’s price target on Medicus Pharma (MDCX) to $20 from $10 and keeps a Buy rating on the shares. The firm cites the company’s Antev acquisition, which brings Teverelix, a next-generation GnRH antagonist with Phase 2b- ready trials in both acute urinary retention – AUR – recurrence prevention and advanced prostate cancer with high cardiovascular risk, the analyst tells investors in a research note. AUR recurrence prevention represents an over $2B opportunity with no approved therapies and 500K recurrent patients per year, the firm adds.